Breast and the prostate are the most prevalent forms of cancer amongst women and men respectively. From an ethnic point of view, African-American men are the group with the highest incidence rate of cancer in the United States. Kentucky and Delaware are the U.S. states where the rate of cancer is the highest. New Mexico and Arizona on the other hand have the lowest number of new cancer cases per 100,000 inhabitants.
While incidence rates are increasing, cancer death rates have constantly fallen since 1990. Men have a higher risk of mortality from cancer than women. African-Americans are the ethnic group with the highest number of cancer-related deaths per 100,000 inhabitants. Lung and bronchial cancer cause the highest number of cancer-related deaths. Approximately 70,500 women and 84,600 men die from this type of cancer annually. The chance of surviving for a five-year period upon diagnosis has increased from 49 percent in the 1970s to 69 percent nowadays.
The cancer drug market is among the top pharmaceutical therapeutic areas both in the United States, and worldwide. Expenditure on oncological medicine in the U.S. was worth some 45.5 billion U.S. dollars in 2016. The top cancer drug worldwide is Roche’s Rituxan, generating 7.1 billion U.S. dollars of revenue in 2015. The United States is a top global developer of new cancer drugs. As of autumn 2015, the number of cancer medicines in development was 836. Among them, the largest groups were aimed at treating solid tumors, lung cancer, and leukemia.